Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants

Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants

We compared the risks of switching to another oral anticoagulant (OAC) and discontinuation of direct oral anticoagulants (DOACs) among elderly patients with nonvalvular atrial fibrillation (NVAF) who were prescribed rivaroxaban or dabigatran versus apixaban. Patients (≥65 years of age) with NVAF pre...

Full description

Bibliographic Details
Main Authors: Christine L. Baker JD, MPH, Amol D. Dhamane BPharm, MS, Jigar Rajpura PhD, Jack Mardekian PhD, Oluwaseyi Dina MPH, Cristina Russ MD, PhD, Lisa Rosenblatt MD, MPH, Melissa Lingohr-Smith PhD, Jay Lin PhD, MBA
Format: Article
Language:English
Published: SAGE Publishing 2019-08-01
Series:Clinical and Applied Thrombosis/Hemostasis
Online Access:https://doi.org/10.1177/1076029619870249

Internet

https://doi.org/10.1177/1076029619870249

Similar Items